The Amanta Healthcare IPO is one of the most anticipated public offerings in India’s healthcare sector for 2025, drawing substantial attention for its growth prospects, robust financials, and grey market premium (GMP) trends. Below is a comprehensive, long-form analysis that covers every major aspect—from GMP trends to financial breakdown, listing outlook, and essential FAQs.
Overview of Amanta Healthcare IPO
Key Details
Amanta Healthcare’s IPO opens for subscription on September 1, 2025, with a price band set at ₹120–₹126 per share and a minimum application lot of 119 shares, translating to around ₹14,994 for retail investors. The company aims to raise about ₹126 crore through a 100% fresh issue, with listing scheduled for September 8–9, 2025 on both BSE and NSE.
GMP Trends and Listing Premium Expectation
Grey Market Premium (GMP) Insights
- The GMP for Amanta Healthcare IPO has fluctuated between ₹21 and ₹28 leading up to the subscription period (Aug 26–Sept 1), peaking at ₹28 just before the IPO opening.
- Recent GMP values suggest a likely listing price between ₹151–₹154, which is around 22% higher than the upper price band of ₹126.
- Strong GMP is typically viewed as a signal of robust demand, though being speculative, it should not be the sole basis for investment decisions.
Factors Influencing GMP
- High demand due to sector growth and Amanta’s niche in sterile liquid pharmaceuticals.
- Improved profitability and expanding international reach.
- Limited supply, with only a fresh issue and no offer-for-sale (OFS).
Financials: Year-on-Year Performance
Revenue and Profitability
| Year Ended | Revenue (₹ Cr) | PAT (₹ Cr) | Assets (₹ Cr) | Net Worth (₹ Cr) | EBITDA (₹ Cr) | Debt (₹ Cr) |
| Mar 2025 | 276.09 | 10.50 | 381.76 | 96.39 | 61.05 | 195 |
| Mar 2024 | 281.61 | 3.63 | 352.12 | 66.29 | 58.76 | 205.23 |
| Mar 2023 | 262.70 | -2.11 | 374.06 | 62.88 | 56.31 | 215.66 |
- The company’s profit after tax (PAT) surged by 189% in FY25, and EBITDA remains healthy at above ₹60 crore.
- Revenue growth is steady, though modest, while debt levels are on a declining trajectory.
- Net worth and reserves have improved, signals strengthening balance sheet.
Use of IPO Proceeds
- ₹70 crore to expand SteriPort manufacturing.
- ₹30 crore for a new SVP line.
- ₹25+ crore towards general corporate purposes.
Business Profile and Market Position
Operations
Amanta Healthcare specializes in sterile injectables, IV fluids, ophthalmic solutions, and other medical devices. It operates a large, certified facility in Gujarat with high capacity utilization (96% as of FY25). Its products are globally distributed—Africa, Latin America, UK, and more.
Strengths
- Strong domestic and international distribution.
- Certifications from over 120 jurisdictions.
- Wide product portfolio and innovative manufacturing technology.
Risks
- High customer concentration.
- Operational risk due to reliance on a single facility.
- Volatility in material supply/pricing and pending litigations.
Listing Expectations: Key Considerations
Valuation & Recommendations
- At ₹126 per share, the IPO is priced at a P/E ratio of 47x post-issue FY25 earnings, indicating a fully valued offering but reflecting sector growth opportunities.
- Most brokerages and analysts recommend subscribing for listing gains due to strong GMP, growing sector tailwinds, and improved profitability.
- However, long-term investors should account for the valuation, operational risk, and sector volatility.
Timelines
- Allotment: September 4, 2025.
- Refunds: September 5, 2025.
- Listing: September 8–9, 2025.
FAQs: Amanta Healthcare IPO
- What is Amanta Healthcare IPO’s price band and lot size?
Amanta Healthcare IPO price band is ₹120–₹126 per share; the minimum lot is 119 shares.
- What are the IPO dates—subscription and listing?
Subscription: September 1–3, 2025; Allotment: September 4; Listing: September 8–9.
- What is the GMP for Amanta Healthcare IPO?
GMP trends between ₹21–₹28 in the week leading to opening; anticipates a ~22% listing premium.
- How has the company performed financially in recent years?
PAT increased nearly 3x from FY24 to FY25, with revenue stable and EBITDA strong.
- What are the main risks associated with the IPO?
High customer concentration, operational risk from a single facility, valuation risk, and raw material price volatility.
- What will the IPO proceeds be used for?
Capacity expansion (SteripPort, SVP) and general corporate purposes.
- Is the IPO recommended for subscription?
Most experts suggest subscribing for listing gains amid strong GMP and demand, but long-term investors should review financials and risk profile.
Final Thoughts
Amanta Healthcare’s IPO stands out due to sectoral growth tailwinds, sharp profitability improvements, and strong market interest reflected in the GMP. Investors looking for short-term gains may find the listing premium attractive. For long-term, prudent due diligence is essential, weighing operational, valuation, and sectoral risks alongside growth potential.
For real-time GMP updates, financial disclosures, and allotment status, refer to the brokerage platforms and official regulatory filings before applying.
